Management of cyclic vomiting syndrome in adults: Evidence review
| Autor: | Christopher D Stave, Kathleen Adams, Shahnaz Sultan, Robert M. Issenman, Raj Shah, B. U. K. Li, Ravi Sharaf, David J. Levinthal, William L. Hasler, Sally E. Tarbell, Thangam Venkatesan, Irene Sarosiek, Safwan Jaradeh |
|---|---|
| Přispěvatelé: | Pediatrics |
| Rok vydání: | 2019 |
| Předmět: |
Topiramate
medicine.medical_specialty Physiology Vomiting Zonisamide Triptans Review Article The Guidelines on Management of Cyclic Vomiting Syndrome (CVS) in Adults technical review Ondansetron 03 medical and health sciences 0302 clinical medicine Medicine Humans Intensive care medicine Review Articles Aprepitant treatment Endocrine and Autonomic Systems business.industry Cyclic vomiting syndrome Gastroenterology Guideline medicine.disease 3. Good health Treatment Outcome Antiemetics 030211 gastroenterology & hepatology Levetiracetam cyclic vomiting business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Neurogastroenterology and Motility |
| Popis: | Background This evidence review was conducted to inform the accompanying clinical practice guideline on the management of cyclic vomiting syndrome (CVS) in adults. Methods We followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework and focused on interventions aimed at prophylactic management and abortive treatment of adults with CVS. Specifically, this evidence review addresses the following clinical questions: (a) Should the following pharmacologic agents be used for prophylaxis of CVS: amitriptyline, topiramate, aprepitant, zonisamide/levetiracetam, or mitochondrial supplements? (b) Should the following pharmacologic agents be used for abortive treatment: triptans or aprepitant? Results We found very low‐quality evidence to support the use of the following agents for prophylactic and abortive treatment of CVS: amitriptyline, topiramate, aprepitant, zonisamide/levetiracetam, and mitochondrial supplements. We have moderate certainty of evidence for the use of triptans as abortive therapy. We found limited evidence to support the use of ondansetron and the treatment of co‐morbid conditions and complementary therapies. Conclusions This evidence review helps inform the accompanying guideline for the management of adults with CVS which is aimed at helping clinicians, patients, and policymakers, and should improve patient outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|